Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DiaTech Oncology Test Shows Positive Results

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Test identifies new therapeutic strategies for patients with lung cancer and ovarian cancer.

DiaTech Oncology has developed a predictive test that has been effective in clinical trials in helping oncologists determine the best chemotherapy treatment plans and therapeutic strategies for more than 50 types of cancers. The company has just published detailed results of the clinical trials for mesothelioma lung cancer, small-cell lung cancer (NSCLC) and advanced stage III and IV ovarian cancer at the American Society of Clinical Oncology (ASCO) conference held in Chicago.

The ASCO event, considered the world’s premiere oncology conference, features cutting-edge scientific presentations and attracts more than 25,000 oncology professionals yearly.

In previous clinical trials and published research, DiaTech Oncology’s predictive test – the MiCK® assay or Correct Chemo™ – showed an increase in complete or partial response rates, longer time to relapse and longer survival times for multiple types of cancer, including acute myeloid leukemia, lymphoma and non-Hodgkin lymphoma, and breast, bladder, ovarian, endometrial and lung cancers.

DiaTech has conducted extensive research on patients with ovarian cancer; however, the results published at ASCO were the first for advanced stage III and IV ovarian cancer or ovarian cancer patients who have relapsed and have resistance to one of the most commonly used chemotherapy drugs, carboplatin. Trial results showed that the MiCK assay can identify alternative chemotherapy treatments for ovarian cancer patients who have relapsing disease and carboplatin resistance.

Clinical results published at ASCO for mesothelioma are significantly notable because there are limited therapies currently available for this rare disease, which medical experts regard as one of the most aggressive and deadly of all cancers. The study was able to identify new chemotherapy strategies that could possibly help control mesothelioma in individual patients.

“DiaTech is the only test on the market that guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient,” says Cary Presant, M.D., DiaTech Chief Medical Officer. “Our clinical tests consistently reveal longer survival times and lower costs for chemotherapy cancer patients. We will carry on in our important work with our key institutional research partners. Our studies are yielding unexpected new leads for innovative therapeutic strategies.“


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!